Booz Allen is in a sustained downtrend that has only recently shown signs of stabilization. The stock is down 26.91% over the past year and 10.59% year-to-date, a dramatic underperformance versus the S&P 500's +16.22% one-year and +12.08% YTD gains, producing a relative strength of -43.13% over twelve months. At the current price of $75.90, the stock sits at roughly 35.5% of its 52-week range (low of $59.50, high of $109.10), meaning it is trading in the lower third of its annual band — a positioning that reflects damaged momentum but also potential value if the fundamental narrative stabilizes. The max drawdown of -46.51% underscores how severe the de-rating has been, and the fact that price is 30.4% below the 52-week high confirms this is a recovery candidate rather than a momentum leader.

Short-term momentum is mixed and suggests the selling pressure is easing. The stock is down 3.19% over the past month and 1.95% over three months, both modest declines that are far less severe than the 26.91% one-year drawdown, indicating deceleration of the downtrend rather than acceleration. Notably, the 1-month relative strength of -2.13% versus SPY is a significant improvement from the -43.13% one-year figure, implying the stock has begun to close the performance gap. The daily price change of +0.29% and the recent bounce from the June low of $59.71 to the current $75.90 — a 27.1% recovery off the bottom — suggest buyers are stepping in around the $60-$65 zone, though the failure to reclaim the $80 level keeps the intermediate trend technically neutral at best.

Key technical levels are well-defined. Immediate support sits at the 52-week low of $59.50, with the June closing low of $59.71 reinforcing that zone as a critical floor; a breakdown below $59.50 would signal a resumption of the primary downtrend and likely target new lows. Resistance is anchored at the 52-week high of $109.10, but the more actionable near-term resistance is the $80-$85 area where the stock repeatedly stalled in April and August 2026. A breakout above $85 on volume would confirm a trend reversal and open the path toward the mid-$90s. The beta of 0.365 is unusually low, indicating the stock is roughly 64% less volatile than the broader market — a defensive characteristic that limits downside velocity but also means rallies may lack the explosive upside of higher-beta peers, which matters for position sizing and risk budgeting.

Booz Allen's revenue trajectory has turned negative, which is the central fundamental concern. The most recent quarter (ending 2026-03-31) reported revenue of $2.783 billion, a YoY decline of 6.44% — a notable reversal from the prior-year quarter's $2.975 billion. The multi-quarter trend shows sequential softening: revenue was $2.924 billion in Q1 FY2026, $2.890 billion in Q2, $2.620 billion in Q3, and $2.783 billion in Q4, with the Q3 figure representing the weakest print. The contract mix — $1.601 billion cost-reimbursable, $632 million time-and-materials, and $550 million fixed-price — is heavily weighted toward lower-margin cost-reimbursable work, which limits operating leverage. The revenue decline implies the investment case now hinges on whether federal AI and defense modernization spending can reaccelerate growth, rather than on the steady mid-single-digit expansion investors previously priced in.

Profitability remains solid but is under pressure. The company generated net income of $205 million in the most recent quarter on a net margin of 7.59%, with gross margin of 20.91% and operating margin of 9.75%. However, comparing across quarters reveals compression: gross margin was 51.9% in Q3 FY2026 and 53.6% in Q2 FY2026 on a different reporting basis, while the Q4 figure of 20.88% reflects the full-cost accounting presentation. Net income has been relatively stable — $205 million, $200 million, $175 million, and $269 million over the last four quarters — but the trailing EPS of $0.088 is alarmingly low relative to the quarterly diluted EPS of $1.69, suggesting significant one-time items or a data reconciliation issue. The operating margin of 9.75% is thin for a consulting firm and reflects the cost-plus nature of government contracting, where margins are structurally capped.

Balance sheet and cash flow metrics reveal a leveraged but cash-generative business. The debt-to-equity ratio of 3.73 is very high, and the company equity multiplier of 6.70 confirms heavy reliance on debt financing, though the current ratio of 1.78 and quick ratio of 1.78 indicate adequate short-term liquidity. Free cash flow on a trailing twelve-month basis is $951 million, with quarterly FCF ranging from $96 million to $395 million, and the most recent quarter delivered $212 million. ROE of 77.01% is exceptionally high but is inflated by the leveraged capital structure rather than superior returns on assets, as ROA is a more modest 9.19%. The dividend yield of 2.87% with a payout ratio of 32.4% is sustainable, and the company continues to return capital via buybacks ($77 million in the latest quarter) and dividends ($71 million), but the high debt load limits financial flexibility if revenue continues to decline.